Eagle Pharmaceuticals, Inc. · OTC:EGRX

Eagle Pharmaceuticals — Merger or Acquisition (March 2022)

32 slides from Eagle Pharmaceuticals's merger presentation, Mar 31, 2022

  1. Slide 1: Investor Update 3/31/2022

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 1 Investor Update 3/31/2022

  2. Slide 2: Forward-Looking Statements

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other securities laws. Forward - loo

  3. Slide 3: Draft Agenda

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 3 Draft Agenda 1 Eagle Strategic Update Scott Tarriff & Brian Cahill 8:30 – 8:45AM 2 BARHEMSYS ® & BYFAVO ® Overview Michael Moran & Michael Greenberg 8:45 – 9:05AM 3 Landiolol Overview Michael Moran & Michael Greenber

  4. Slide 4: Eagle's Strategy is to Evolve into a Diversified, Branded Pharmaceutical Company

    4 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 4 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. Eagle’s Strategy is to Evolve into: A Diversified, Branded Pharmaceutical Company with Assets in Oncology + Acute Care Specialty Pha

  5. Slide 5: Proposed Acacia Transaction Rationale

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 5 Proposed Acacia Transaction Rationale Eagle’s proposed acquisition of Acacia is a significant step in our journey to become a leading pharmaceutical company focused on innovative hospital and oncology products x Oppo

  6. Slide 6: Hospital Patient Volume is Slowly Returning

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 6 Hospital Patient Volume is Slowly Returning with Physicians Expecting Volumes to Exceed Pre - COVID Levels in the 2 nd Half of 2022 92% 99% 100% 101% 106% Q4 2021 (Oct. - Dec.) Q1 2022 (Jan. - March) Q2 2022 (April -

  7. Slide 7: Eagle Pharmaceuticals Financial Position, Portfolio & Pipeline

    7 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. Eagle Pharmaceuticals Financial Position, Portfolio & Pipeline Share Buybacks $230M or 24% Net Working Capital of $98.2M Total Cash and Cash Equivalents $97.7M **Strategic collaboration with Tyme Technologies Strong

  8. Slide 8: Proposed Transaction Details

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 8 Proposed Transaction Details Transaction Terms • 75% cash, 25% stock transaction, values Acacia at approximately €94.7 million ($104 million) • Acacia shareholders would receive total consideration of €0.90 per share

  9. Slide 9: Additional Financial Information

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 9 Additional Financial Information Transaction expected to be earnings accretive in 2024 Eagle plans to continue Acacia’s post marketing commitments to FDA for Phase IV pediatric studies on BARHEMSYS and BYFAVO Acacia

  10. Slide 10: BARHEMSYS and BYFAVO Overview

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 10 10 BARHEMSYS ® and BYFAVO ® Overview

  11. Slide 11: BARHEMSYS (amisulpride for injection)

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 11 11 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. BARHEMSYS ® (amisulpride for injection) The first and only FDA - approved p r odu c t f o r P O N V r esc u e t r ea tme n t 1 1 F

  12. Slide 12: BARHEMSYS and Potential PONV Commercial Opportunity

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 12 BARHEMSYS ® and Potential PONV Commercial Opportunity • BARHEMSYS is the only FDA - approved drug for PONV rescue after failed prophylaxis 1 • Selective d opamine D 2 /D 3 antagonist with broad, differentiated label

  13. Slide 13: Targeting PONV Rescue Market in the US

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 13 Targeting PONV Rescue Market in the US Total estimated addressable market in PONV rescue $ 0 .7B per year 1 1 Based on m arket research performed by or for Eagle . ~70m surgical patients annually receive antiemetic

  14. Slide 14: BARHEMSYS is the Only FDA-Approved Product for PONV Rescue

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 14 BARHEMSYS ® is the Only FDA - Approved Product for PONV Rescue Antiemetic Can’t redose Efficacy issues Safety issues Current share of rescue patients Ondansetron ػ 1 69% Dexamethasone ػ 1 ػ 2 19% Metoclopramide ػ 1

  15. Slide 15: BARHEMSYS – Compelling Commercial Potential

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 15 BARHEMSYS – Compelling Commercial Potential Significant unmet need • Nausea more so than vomiting, worse than pain • Consensus Guidelines: “When PONV prophylaxis has failed, patients should receive antiemetic treatm

  16. Slide 16: BYFAVO (remimazolam) for injection

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 16 16 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. BYFAVO ® (remimazolam) for injection Rapid onset/offset procedural sedative with favorable safety profile

  17. Slide 17: Procedural Sedation US Potential Addressable Market

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 17 Procedural Sedation US Potential Addressable Market ~ 4 0 m illi on 1 procedures each year requiring sedation ~25 million GI procedures performed each year 2 >80% GI procedures have sedation administered by an anest

  18. Slide 18: BYFAVO Addresses Unmet Need in Procedural Sedation

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 18 BYFAVO Addresses Unmet Need in Procedural Sedation • Rapid onset and offset anesthetic with narrow therapeutic index 1 • Dose - related cardiorespiratory depression , pain at injection site 1 • Non - linear dosing e

  19. Slide 19: Rapid Onset/Offset with a Favorable Safety Profile

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 19 R ap i d O n s e t / O ff s e t w i t h a F av o r a bl e S a fe t y P r o file 1 13 19 6 4 0 BYFAVO Midazolam Minutes to fully alert after procedure Minutes to procedure start BYFAVO Midazolam Any adverse event 74%

  20. Slide 20: BYFAVO – Compelling Commercial Proposition

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 20 BYFAVO – Compelling Commercial Proposition Clear unmet need • No innovation in the sedation space for 20+ years • Customers seeking fast onset, titratable and rapid recovery for quick discharge • Shorter procedure t

  21. Slide 21: Landiolol

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 21 21 Landiolol

  22. Slide 22: Landiolol – Investigational Drug Candidate in the US – Key Facts

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 22 Landiolol – Investigational Drug Candidate in the US - Key Facts • Ultra - short acting cardioselective β1 - blocker • Rapid control – Supraventricular tachycardia – Ventricular rate • Simple intravenous dosing • Mu

  23. Slide 23: US Potential Addressable Market Considerations

    23 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. US Potential Addressable Market Considerations 305 , 788 Esmolol 1 , 201 , 377 Amiodarone 1 , 039 , 691 1 , 661 , 127 1 , 043 ,2 32 338 , 289 Arrhyth m ias Ischemia Operation (non cardiac, risk patients) Other (aort

  24. Slide 24: Summary on Landiolol Potential Addressable Market

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 24 Summary on Landiolol Potential Addressable Market • Landiolol, if approved by the FDA, is expected to get its volume sales from current Esmolol and Amiodarone (injectables) markets • Esmolol market (all injectables)

  25. Slide 25: Landiolol Potentially Addresses an Important Unmet Clinical Need

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 25 Landiolol Potentially Addresses an Important Unmet Clinical Need ● Plan to file NDA in May 2022 ● Seeking approval of landiolol for use in patients in whom it is necessary to safely and rapidly reduce heart rate – I

  26. Slide 26: Landiolol Features from Clinical Data Expected to be in the NDA

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 26 Landiolol Features from Clinical Data Expected to be in the NDA 1. Krumpl G, et al. Eur J Clin Pharmacol. 2017;73(4):417 - 428. 2. McKee JS, et al. Anesthesiology. 2014;121(6):1184 - 1193. 3. Shibata S, et al. J Pha

  27. Slide 27: Landiolol Features from Clinical Data Expected to be in the NDA

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 27 Landiolol Features from Clinical Data Expected to be in the NDA COPD, chronic obstructive pulmonary disease; CYP450, cytochrome P450 1. Landiolol. Summary of Product Characteristics, current version. 2. Krumpl G, et

  28. Slide 28: Landiolol – Compelling Commercial Proposition

    28 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. Landiolol – Compelling Commercial Proposition Potentially Substantial Commercial Opportunity – Potential to expand β - blocker market – Anticipated health economic benefits – Aligns with Eagle’s hospital - based sal

  29. Slide 29: Question & Answer

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 29 29 Question & Answer

  30. Slide 30: Appendix

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 30 30 Appendix

  31. Slide 31: BARHEMSYS Indications and ISI

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 31 BARHEMSYS Indications and ISI Indication BARHEMSYS is a selective dopamine - 2 (D 2 ) and dopamine - 3 (D 3 ) receptor antagonist indicated in adults for: • prevention of postoperative nausea and vomiting (PONV), ei

  32. Slide 32: BYFAVO Indication and ISI

    CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 32 BYFAVO Indication and ISI Indication BYFAVO is a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Important Safety Informa

Eagle Pharmaceuticals — Merger or Acquisition (March 2022) on 6ix